Abattis signs Andrew Riseman, Ph.D. Associate Professor, Applied
Biology and Plant Breeding
VANCOUVER, Jan. 14, 2013 /PRNewswire/ - Abattis Bioceuticals
Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU),
announces the engagement of Andrew Riseman Ph.D. effective
January 11, 2013. Dr. Riseman will be
assisting the Company in Applied Biology and Plant Sciences.
Mr. Mike Withrow, Chief Executive
Officer on behalf of the Company, stated, "We are pleased to have
Dr. Riseman join our Abattis team. His expertise in tissue and
plant breeding sciences will be a tremendous asset to Abattis; we
will apply his knowledge to produce proprietary intellectual
property for the company. "
Andrew Riseman Ph.D., Associate Professor, Plant
Biology and Plant Breeding at UBC stated, I am very excited about
this opportunity to work with such a great company to advance
botanical sciences in the Medical Marijuana and other medicinal
plant breeding sciences, I see Abattis a company with the ability
to engineer, grow and extract advanced Pharmaceutical Grade
Compounds "PGC's" that ensure traceability, consistency in dosing
and safety with a target to produce the purest compounds from
chosen cultivars."
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company
with capabilities through its wholly owned subsidiaries of
producing, licensing and marketing proprietary ingredients and
bio-similar compounds for use in Pharmaceuticals, Nutraceutical,
Cosmetic and Animal Nutrition markets. The company also has a deep
pipeline of proprietary products ready for sale in high growth
areas of Functional Foods and Supplements business. For more
information, visit the Company's website at www.abattis.com.
About Dr. Riseman
http://www.landfood.ubc.ca/directory/faculty/professors-and-instructors/andrew-riseman
ON BEHALF OF THE BOARD
'Mike
Withrow' |
Michael Withrow, President & CEO |
Neither the CNSX Exchange nor its regulations
services accepts responsibility
for the adequacy or accuracy of this release.
SOURCE Abattis Bioceuticals Corp.